Immunome (IMNM) CBO Horn Kinney Receives RSU Awards

What Happened Horn Kinney, Chief Business Officer of Immunome (IMNM), was granted a total of 93,750 equity awards on July 23, 2026. The filing reports 31,250 shares acquired (RSUs) at $0.00 and 62,500 derivative awards acquired at $0.00. These were awards/grants (code A) rather than open‑market purchases or sales, so no cash changed hands at grant.

Key Details

• Transaction date: July 23, 2026; Form 4 filed July 27, 2026 (timely under the 2-business‑day rule).
• Award amounts: 31,250 shares (RSUs) + 62,500 derivative awards = 93,750 total.
• Price: $0.00 per share (standard for grants/RSUs at time of award); reported transaction value = $0.
• Shares owned after transaction: not specified in the provided filing details.
• Footnote F1: The 31,250 (and likely part of the derivative awards) are RSUs — each RSU converts to one share upon settlement; 25% of these RSUs vest and settle annually on each anniversary of the grant, subject to continued service.
• Footnote F2: The filing also notes an option‑style vesting schedule (25% vest on July 23, 2027, then 1/36th monthly thereafter) for related awards; this describes multi‑year vesting terms referenced in the filing.

Context This was a compensation award (grant of RSUs/derivative awards), which is routine for executives and not an open‑market purchase or sale. Such grants are typically part of long‑term incentive pay and are subject to vesting, so they do not represent an immediate change in market exposure.